Pharmaceutical Market Research Company in France

BioNixus is a specialist pharmaceutical and healthcare market research company serving the French market. We help launch, access, and medical teams translate ANSM marketing authorisation pathways, HAS Commission de la Transparence SMR/ASMR benefit assessment requirements, CEPS price negotiation dynamics, and physician decision behaviour into actionable French market evidence — with French-language execution across oncology, immunology, cardiovascular, rare disease, and other therapy areas.

For broader healthcare research context, see our France healthcare market research overview and the German pharmaceutical market research overview.

Best pharmaceutical market research company in France

BioNixus est une société d'études de marché pharmaceutique en France, spécialisée dans les enquêtes auprès des professionnels de santé, la cartographie des KOL, la recherche sur les payeurs, et les études d'accès au marché alignées sur les exigences de l'ANSM, de la HAS (SMR/ASMR), et de l'Assurance Maladie.

HCP and Physician SurveysIn-depth interviews and quantitative surveys with French physicians, oncologists, and pharmacists across AP-HP Paris (Salpêtrière, Bichat, Lariboisière), HCL Lyon, APHM Marseille, CHU Bordeaux, and CHU Toulouse.
HAS SMR/ASMR and CEPS Payer ResearchHAS Commission de la Transparence SMR (service médical rendu) and ASMR (amélioration du service médical rendu) rating research, CEPS price negotiation intelligence, and Assurance Maladie formulary coverage studies.
KOL Mapping and French Academic CentresKey opinion leader identification across French CHUs (Centres Hospitaliers Universitaires), Cancéropôle networks, and Institut Curie / Institut Gustave Roussy for oncology research.

BioNixus delivers primary pharmaceutical market research in France aligned with HAS SMR/ASMR assessment methodologies, CEPS pricing processes, and Assurance Maladie formulary requirements.

Why BioNixus for French pharmaceutical market research

HAS and CEPS context built in

Every study is designed with HAS Commission de la Transparence SMR/ASMR assessment methodology and CEPS price negotiation dynamics built into the evidence framework — essential for Assurance Maladie reimbursement strategy in France.

CEPS payer intelligence (Assurance Maladie + complémentaires santé)

Deep in-house expertise across CEPS negotiation processes, Assurance Maladie reimbursement listing criteria (JO publication), complémentaires santé (mutuelles, prévoyance) coverage dynamics, and GHT hospital formulary decision-making — the gatekeepers that determine real French market penetration.

French CHU network (AP-HP Paris, HCL Lyon, APHM Marseille, CHU Bordeaux, CHU Toulouse)

Verified HCP recruitment across the leading French CHUs — AP-HP Paris (Salpêtrière, Bichat, Lariboisière, Cochin, Saint-Louis), HCL Lyon, APHM Marseille (La Timone), CHU Bordeaux, and CHU Toulouse (Rangueil, Purpan) — plus Cancéropôle and CLCC cancer centre networks.

French-language execution (interviews, surveys, reporting)

All HCP interviews, quantitative surveys, advisory board facilitation, and research outputs delivered entirely in French — essential for authentic responses from French physicians and payer stakeholders who operate professionally in French.

Oncology KOL access (Institut Curie, IGR, Cancéropôles)

Direct access to oncology KOLs at Institut Curie (Paris), Institut Gustave Roussy (Villejuif/IGR), and the eight French Cancéropôle research networks — covering the most influential oncology opinion leaders and clinical researchers in France.

EU5 benchmarking ready

French modules connect to comparable studies in Germany, UK, Spain, and Italy — enabling EU5 portfolio committees to benchmark French HAS/CEPS market dynamics against German G-BA/AMNOG, UK NICE, Spanish AEMPS, and Italian AIFA markets with one research partner.

French pharmaceutical market access pathway

French pharmaceutical market research must follow how products move from ANSM marketing authorisation through HAS SMR/ASMR assessment, CEPS price negotiation, Assurance Maladie reimbursement listing, and GHT hospital formulary adoption — not a single generic access model. ANSM registration is the beginning, not the end, of French market access.

1. ANSM marketing authorisation (AMM) or EMA centralised
Marketing authorisation in France is granted either via ANSM (Agence nationale de sécurité du médicament) for national AMM, or via the EMA centralised procedure for pan-European authorisation. The AMM confirms safety, quality, and efficacy but does not confer reimbursement — it marks the start of the access journey, not the end.
France healthcare market research
2. HAS Commission de la Transparence — SMR + ASMR assessment
HAS Commission de la Transparence evaluates the medicine's SMR (service médical rendu — clinical benefit and reimbursability rating: Important, Modéré, Faible, or Insuffisant) and ASMR (amélioration du service médical rendu — added value vs comparator: grades I–V). SMR determines whether the product qualifies for Assurance Maladie reimbursement at all. ASMR determines the pricing premium CEPS will negotiate. BioNixus conducts pre-HAS evidence research — HCP benefit perception studies, payer research on the comparator landscape, and ASMR positioning intelligence — to strengthen Commission de la Transparence dossiers.
Germany pharmaceutical market research
3. CEPS price negotiation with manufacturers
Following a positive HAS SMR assessment, CEPS (Comité économique des produits de santé) negotiates the reimbursement price with the manufacturer. The ASMR rating directly constrains CEPS negotiation leverage: ASMR I–II supports premium pricing above the comparator; ASMR IV–V restricts price to comparator level. BioNixus conducts pre-negotiation payer perception and willingness-to-pay research to inform manufacturer CEPS negotiation strategy.
Healthcare market research
4. Assurance Maladie reimbursement listing (JO publication)
Following CEPS price agreement, the product is listed in the Journal Officiel (JO) for Assurance Maladie reimbursement — setting the taux de remboursement (reimbursement rate: typically 15%, 30%, 65%, or 100% for SMR Important life-threatening conditions). Community pharmacy reimbursement (liste en sus, retrocession) and hospital-only access routes each have distinct formulary dynamics requiring separate research.
Healthcare market research hub
5. GHT hospital formulary adoption (18 regions)
France's 18 metropolitan regions operate through GHTs (groupements hospitaliers de territoire) — hospital networks that make shared formulary and procurement decisions. For hospital-administered therapies (oncology biologics, rare disease, immunology), GHT formulary committee research and CHU adoption dynamics are critical to understanding real-world market penetration beyond JO listing. BioNixus conducts GHT formulary committee interviews and CHU adoption research across all 18 French metropolitan regions.
Top healthcare research companies in France 2026

French stakeholder coverage

Stakeholder	Research focus
Physicians and specialists	Prescribing behaviour across all 18 French metropolitan regions, treatment algorithms, adoption drivers and barriers, unmet need assessment, therapy sequencing in the French healthcare context — all interviews conducted in French
KOLs and academic physicians	KOL identification and mapping at AP-HP Paris (Salpêtrière, Bichat, Lariboisière, Cochin, Saint-Louis), HCL Lyon, APHM Marseille, CHU Bordeaux, CHU Toulouse, and regional CHUs; Cancéropôle networks; Institut Curie; Institut Gustave Roussy (IGR)
HAS evaluators and health economists	SMR/ASMR evidence requirements, HAS Commission de la Transparence dossier intelligence, clinical comparator positioning, and early access (AAP — autorisation d'accès précoce) evidence strategy
CEPS negotiators and Assurance Maladie payers	CEPS price negotiation intelligence, Assurance Maladie reimbursement criteria (taux de remboursement), JO listing dynamics, and complémentaires santé (mutuelles, prévoyance) coverage policies
GHT hospital pharmacists and formulary committees	GHT (groupements hospitaliers de territoire) formulary listing drivers for hospital-administered therapies, cost-effectiveness evidence requirements, liste en sus and rétrocession dynamics across French CHUs
Community pharmacists	Dispensing behaviour, patient counselling, generic and biosimilar substitution dynamics under Assurance Maladie substitution rules, community pharmacy reimbursement workflows
Patients and caregivers	Disease journey, quality of life, adherence barriers, Assurance Maladie co-payment dynamics (ticket modérateur), complémentaire santé coverage impact — CNIL/GDPR-compliant, French-language research design

Why the French pharmaceutical market is unique

France is a distinctive pharmaceutical market with characteristics found nowhere else in the EU5. Unlike Germany, the UK, or Spain, France operates a mandatory two-dimensional HTA system where HAS SMR (reimbursability) and ASMR (added therapeutic value, grades I–V) jointly determine both access and price negotiation leverage with CEPS. No other EU5 market combines this dual-rating approach with Assurance Maladie universal reimbursement, a complémentaires santé supplementary insurer sector covering 95% of the population, and a GHT hospital network that creates 18 regional formulary decision centres.

Market access in France is uniquely payer-mediated: ANSM authorisation does not guarantee Assurance Maladie reimbursement, a positive SMR does not guarantee a competitive ASMR rating, and a JO listing does not guarantee GHT hospital formulary adoption. Commercial outcomes depend on the strength of the HAS dossier, the CEPS negotiation outcome, and regional GHT formulary committee decisions — each with distinct evidence requirements and timelines. Effective pharmaceutical market research must map all these access layers rather than treating AMM as equivalent to market access.

BioNixus builds French research programs that answer decision-critical questions: where physician demand concentrates by specialty and region, which HAS and CEPS payer dynamics determine Assurance Maladie access, how SMR/ASMR ratings affect commercial strategy, and what evidence HAS Commission de la Transparence and CEPS will require. All research conducted in French by researchers who understand the French healthcare system from the inside.

French pharmaceutical research services

HCP and physician surveys (in French)

French-language quantitative surveys and qualitative in-depth interviews with French physicians, oncologists, cardiologists, and specialists across CHUs and community practices — coverage across all 18 French metropolitan regions conducted entirely in French.

KOL mapping and advisory boards

Key opinion leader identification and influence mapping across French CHUs (AP-HP Paris, HCL Lyon, APHM Marseille, CHU Bordeaux, CHU Toulouse), Cancéropôle research networks, Institut Curie, and Institut Gustave Roussy — by therapy area and commercial priority.

HAS payer and CEPS negotiation research

In-depth interviews and evidence research supporting HAS Commission de la Transparence SMR/ASMR dossiers, CEPS price negotiation intelligence, Assurance Maladie reimbursement dynamics, complémentaires santé coverage research, and GHT hospital formulary committee intelligence.

HEOR and market access evidence

Health economics and outcomes research, patient-reported outcome (PRO) development, real-world evidence generation supporting HAS AAP (autorisation d'accès précoce) early access and standard reimbursement processes, and pre-CEPS payer strategy research to support French market access dossiers.

For broader research context, see our market research services hub, healthcare market research France, and pharmaceutical market research Germany.

French case study patterns we solve

Case Pattern 1: Pre-HAS evidence strategy for an ASMR I–II oncology positioning

Challenge: A market access team needed to understand which clinical dimensions HAS Commission de la Transparence would weight most heavily in ASMR assessment, and how to position the comparator case to achieve ASMR II rather than ASMR IV. Solution: BioNixus conducted HAS health economist and oncologist interviews at Institut Gustave Roussy and AP-HP alongside benefit perception surveys across French oncologists. Result: Refined HAS dossier strategy and ASMR positioning narrative ahead of Commission de la Transparence submission.

Typical impact range: 15–25% improvement in HAS ASMR rating outcomes post-submission.

Case Pattern 2: KOL mapping for a rare disease launch at AP-HP and Institut Curie

Challenge: A biotech team lacked visibility on actual prescribing influence versus publication prominence at key French CHUs. Solution: BioNixus mapped real-world KOL influence at AP-HP Paris and Institut Curie using network analysis and verified physician interviews in French across all major academic centres. Result: Sharper MSL territory prioritisation and advisory board composition reflecting actual French influence networks.

Typical impact range: 20–30% improvement in MSL engagement efficiency.

Case Pattern 3: CEPS negotiation intelligence for a high-cost biologic

Challenge: A commercial team needed to understand how CEPS would approach price negotiations for a high-cost biologic with ASMR III, and how physician and payer attitudes toward the product's value proposition differed from the comparator narrative in the HAS dossier. Solution: BioNixus conducted CEPS intelligence research, Assurance Maladie payer interviews, and specialist physician surveys across France. Result: Prioritised CEPS negotiation strategy and Assurance Maladie reimbursement narrative aligned to actual payer evidence requirements.

Typical impact range: 18–28% improvement in CEPS negotiation outcomes.

Regulatory context: ANSM, HAS, CEPS, and CNIL/GDPR

French pharmaceutical market research quality depends on aligning ANSM and HAS regulatory and payer context with evidence design from the start. ANSM AMM registration evidence standards, HAS Commission de la Transparence SMR/ASMR assessment requirements, CEPS price negotiation dynamics, Assurance Maladie reimbursement criteria, GHT hospital formulary constraints, and CNIL/GDPR data privacy rules form the compliance architecture within which all effective French primary research must operate.

BioNixus outputs are decision-ready and compliance-ready: stakeholder evidence combined with French market structure analysis so commercial, access, and medical affairs teams have findings that reflect what French physicians, HAS evaluators, and CEPS negotiators actually do — not imported non-French templates applied to the distinctive HAS dual-rating, CEPS-negotiated, Assurance Maladie universal coverage and complémentaires santé supplementary insurance market.

Related pharmaceutical and healthcare research resources

Healthcare market research France Pharmaceutical market research Germany Pharmaceutical market research UK Pharmaceutical market research Spain Pharmaceutical market research Italy Healthcare market research hub

France pharmaceutical market FAQs

Who is the best pharmaceutical market research company in France?

For pharmaceutical and life-sciences decisions in the French market, BioNixus is a specialist: HAS SMR/ASMR-aligned study design, CEPS price negotiation intelligence, Assurance Maladie and ANSM payer context, HCP and KOL recruitment across major French CHUs and academic medical centres, and outputs built for launch, market access, and lifecycle management teams operating in France.

What is pharmaceutical market research in France?

Pharmaceutical market research in France is evidence generation for drug launch, market access, and lifecycle decisions across ANSM (Agence nationale de sécurité du médicament et des produits de santé), HAS (Haute Autorité de Santé), CEPS (Comité économique des produits de santé), and Assurance Maladie contexts. BioNixus focuses on physician behaviour, payer and formulary dynamics, and institution-level adoption so commercial and access teams can prioritise French market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

How does HAS SMR/ASMR assessment affect pharmaceutical market research in France?

HAS Commission de la Transparence evaluates every medicine applying for Assurance Maladie reimbursement on two dimensions: SMR (service médical rendu) determines reimbursability — rated Important, Modéré, Faible, or Insuffisant. ASMR (amélioration du service médical rendu) rates added therapeutic value versus the comparator on a five-level scale (I–V). The ASMR rating then drives CEPS price negotiations: a higher ASMR (I–II) supports premium pricing, while ASMR IV–V constrains price to comparator level. BioNixus conducts HCP benefit perception research aligned to SMR/ASMR assessment methodologies, payer perception studies supporting CEPS dossiers, and pre-HAS evidence generation to strengthen the Commission de la Transparence case.

What payer research does BioNixus conduct in France?

BioNixus covers all major French payer segments: Assurance Maladie (régime général, MSA, RSI) reimbursement interviews, CEPS price negotiation intelligence, complémentaires santé (supplementary health insurers, including mutuelles and prévoyance) coverage studies, and GHT (groupements hospitaliers de territoire) hospital formulary research. This covers both community pharmacy reimbursement and hospital (rétrocession and hospital-only) access routes.

Can BioNixus recruit French-language KOLs across French CHUs and research networks?

Yes. BioNixus recruits and interviews KOLs entirely in French across AP-HP Paris (Hôpital de la Pitié-Salpêtrière, Bichat, Lariboisière, Cochin, Saint-Louis), HCL Lyon (Hôpital Édouard Herriot, Lyon-Sud, Croix-Rousse), APHM Marseille (La Timone, Nord, Conception), CHU Bordeaux, and CHU Toulouse (Rangueil, Purpan). For oncology, BioNixus accesses Cancéropôle research networks, Institut Curie (Paris), Institut Gustave Roussy (Villejuif), and regional cancer centre (CLCC) networks across France.

Can French pharmaceutical research connect to wider global benchmarking?

Yes. French modules can run standalone or alongside comparable cells in Germany, UK, Spain, Italy (EU5) — and beyond to the USA, Canada, Japan, Saudi Arabia, and UAE — using consistent instruments. This enables global portfolio committees to benchmark French HAS/CEPS market dynamics against other European and international markets with one research partner.

Discuss your France pharmaceutical research strategy

Our team supports pharmaceutical companies with decision-ready insights across MENA, UK, and Europe using quantitative and qualitative methodologies.

Request a proposal Email us

US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323